Aadi Bioscience, Inc. (AADI) Financial Statements (2024 and earlier)

Company Profile

Business Address 17383 SUNSET AVENUE
PACIFIC PALISADES, CA 90272
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

9/30/2023
MRQ
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:172,600148,98942,60538,52562,61420,264
Cash and cash equivalents39,019148,98942,60538,52562,61420,264
Short-term investments133,541     
Other undisclosed cash, cash equivalents, and short-term investments40     
Receivables1,862     
Inventory, net of allowances, customer advances and progress billings1,861     
Inventory1,861     
Prepaid expense   510311754313
Other current assets   1,604735616322
Other undisclosed current assets3,7062,283    
Total current assets:180,029151,27244,71939,57063,98420,899
Noncurrent Assets
Operating lease, right-of-use asset1,52255764162
Property, plant and equipment5085712216498107
Intangible assets, net (including goodwill)  3,811    
Intangible assets, net (excluding goodwill)  3,811    
Deposits noncurrent assets   20404121
Other noncurrent assets2,1782,213    
Total noncurrent assets:4,2086,638206366139128
TOTAL ASSETS:184,237157,91044,92539,93764,12321,028
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:18,44114,8841,7993,2315,4573,592
Employee-related liabilities 4777331,968903
Accounts payable3,5196,4395234405961,277
Accrued liabilities14,9228,445471360661343
Other undisclosed accounts payable and accrued liabilities   3281,6982,2321,070
Debt    103  
Due to related parties 258    
Other undisclosed current liabilities39413167   
Total current liabilities:18,83515,2731,8673,3345,4573,592
Noncurrent Liabilities
Long-term debt and lease obligation:  474 67  
Liabilities, other than long-term debt1,2675,757    
Due to related parties 5,757    
Operating lease, liability1,267474 67
Other undisclosed noncurrent liabilities 5,757     
Total noncurrent liabilities:7,0246,231 67  
Total liabilities:25,85921,5041,8673,4015,4573,592
Equity
Equity, attributable to parent158,378136,40643,05836,53558,66717,435
Common stock225443
Additional paid in capital361,689279,089189,604178,767177,622125,995
Accumulated other comprehensive loss(115)     
Accumulated deficit(203,198)(142,685)(146,551)(142,236)(118,959)(108,563)
Total equity:158,378136,40643,05836,53558,66717,435
TOTAL LIABILITIES AND EQUITY:184,237157,91044,92539,93764,12321,028

Income Statement (P&L) ($ in thousands)

9/30/2023
TTM
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
Revenues15,2161,12015,000 20,157 
Cost of revenue(1,335)(171)    
Cost of goods and services sold(1,335)     
Provision for loan, lease, and other losses  (171)   
Gross profit:13,88194915,000 20,157 
Operating expenses(76,562)(112,337)(21,357)(24,444)(31,339)(21,389)
Other undisclosed operating income  171    
Operating loss:(62,681)(111,217)(6,357)(24,444)(11,181)(21,389)
Nonoperating income (expense)2,1681,1292,0421,174785(12)
Other nonoperating income2,1681,1291,814   
Interest and debt expense(230)196   (76)
Loss from continuing operations before equity method investments, income taxes:(60,743)(109,892)(4,315)(23,271)(10,397)(21,476)
Other undisclosed income (loss) from continuing operations before income taxes230(196)    
Loss from continuing operations before income taxes:(60,513)(110,088)(4,315)(23,271)(10,397)(21,476)
Income tax expense  (2)    
Other undisclosed income from continuing operations      
Loss from continuing operations:(60,513)(110,090)(4,315)(23,271)(10,397)(21,476)
Loss before gain (loss) on sale of properties:(110,090)(4,315)(23,271)(10,397)(21,476)
Net loss:(60,513)(110,090)(4,315)(23,271)(10,397)(21,476)
Other undisclosed net income attributable to parent     76
Net loss attributable to parent:(60,513)(110,090)(4,315)(23,271)(10,397)(21,401)
Preferred stock dividends and other adjustments      (943)
Net loss available to common stockholders, diluted:(60,513)(110,090)(4,315)(23,271)(10,397)(22,344)

Comprehensive Income ($ in thousands)

9/30/2023
TTM
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
Net loss:(60,513)(110,090)(4,315)(23,271)(10,397)(21,476)
Other comprehensive income (loss)(115)     
Other undisclosed comprehensive loss      
Comprehensive loss:(60,628)(110,090)(4,315)(23,271)(10,397)(21,476)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent (647)    
Comprehensive loss, net of tax, attributable to parent:(60,628)(110,737)(4,315)(23,271)(10,397)(21,476)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: